Balanced news tone
News Sentiment
ASTRAZEN sentiment intelligence
AstraZeneca Pharma India Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-2.3% over one week, -1.6% over four weeks, trend inactive, and near fair-value range.
AstraZeneca Pharma India gets CDSCO nod for additional Fasenra indication
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
AstraZeneca Pharma India gets CDSCO nod for additional Fasenra indication
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 12:46
- Source
- Business Standard
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Jul 2026 05:00
- Source
- CNBC
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 10 Jul 2026 22:15
- Source
- Market source
Lumentum, Sandisk, Applied Materials, AstraZeneca, and More Stocks That Explain Today’s Market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 20:47
- Source
- Barron's
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 20:26
- Source
- Investor's Business Daily
AstraZeneca's Wainua fails key heart disease trial, shares tumble
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 16:05
- Source
- Reuters
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 15:59
- Source
- Clinical Trials Arena
AstraZeneca, Ionis Shares Slide After Wainua Misses Target in Heart Disease Trial
- Tone
- Negative 34/100
- Event
- Analyst action
- Published
- 09 Jul 2026 13:41
- Source
- WSJ
AstraZeneca and Ionis Stock Slump After Trial Miss Is an Overreaction
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 09 Jul 2026 11:38
- Source
- Barron's
AstraZeneca stock drops 9% after Wainua heart drug trial fails
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 11:14
- Source
- qz.com
AstraZeneca sees stock market value slump by more than £20bn after drug setback
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 09 Jul 2026 10:30
- Source
- Market source
AstraZeneca's £19bn blow as Wainua heart drug fails key late-stage trial
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 07:50
- Source
- Market source
AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 09 Jul 2026 07:34
- Source
- CNBC
AstraZeneca shares slide after heart treatment disappoints in trial
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 09 Jul 2026 07:20
- Source
- Financial Times
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 07:00
- Source
- Market source
AstraZeneca Pharma India Ltd appoints Mihir Parikh, Amay Ashok Pandey as Directors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 07:00
- Source
- scanx.trade
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Undervalued After Recent Pullback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Market source
AstraZeneca (LSE:AZN) Stock Fair Value Edges Lower After Pipeline And Pricing Debate
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Market source
Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Market source
AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- Market source
AstraZeneca Pharma India closes trading window until Q1FY27 results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jun 2026 07:00
- Source
- scanx.trade
AstraZeneca Pharma India accepts resignations of two senior executives
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 07:00
- Source
- scanx.trade
We Think That There Are Issues Underlying AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jun 2026 07:00
- Source
- simplywall.st
Here's Why AstraZeneca Pharma India (NSE:ASTRAZEN) Has Caught The Eye Of Investors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- simplywall.st
Astrazeneca Pharma Q4 Profit Drops 23% to ₹44.9 Cr as Margins Shrink to 10.5%
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 27 May 2026 07:00
- Source
- Sahi
AstraZeneca Falls 7% on Q4 Profit Drop, Margin Hit
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 May 2026 07:00
- Source
- HDFC Sky
AstraZeneca Pharma shares slip 6% on posting 23% fall in Q4 profit YoY
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 May 2026 07:00
- Source
- Business Standard
AstraZeneca FY26 revenue rises 33%, recommends ₹36 dividend
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 May 2026 07:00
- Source
- scanx.trade
AstraZeneca falls 7% as Q4 net profit declines 23%; here's a trading strategy for the pharma stock
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 27 May 2026 07:00
- Source
- Moneycontrol.com
AstraZeneca Pharma India Q4 profit drops 23% despite strong revenue growth
- Tone
- Positive 95/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- CNBC TV18